Madrigal Logs Q4 EPS of $2.57, BofA Cuts Price Target to $529
Madrigal Pharmaceuticals reported Q4 EPS of $2.57 and revenue of $321.1 million, prompting Bank of America to cut its price target to $529 with 22% upside. The company logged almost $1B in Rezdiffra sales in 2025 and projects strong 2026 net sales growth from first-line access and rising disease awareness.
1. Q4 Financial Performance
Madrigal reported Q4 EPS of $2.57 on revenue of $321.083 million, modestly above consensus and reflecting ongoing uptake of its MASH therapy Rezdiffra.
2. Bank of America Revises Price Target
Bank of America lowered its price target on Madrigal from $570 to $529, projecting over 22% upside while maintaining a Neutral rating and adjusting forecasts based on management’s gross-to-net comments.
3. Rezdiffra Sales Milestone and 2026 Outlook
The company generated nearly $1 billion in Rezdiffra sales in its first full launch year of 2025 and expects robust 2026 net sales growth driven by expanded first-line access, increasing disease awareness and positive real-world experiences.